Drug-Induced Cardiotoxicity: How to Protect Your Heart
"Protecting the Heart: New Strategies for Predicting and Preventing Cardiotoxic Side Effects of Chemotherapy"
Cancer treatments, while life-saving, can sometimes have unintended consequences for the heart. Cardiotoxicity, or heart damage caused by drugs, is a significant concern in cancer therapy. Many chemotherapeutic agents can lead to a range of cardiovascular issues, from mild arrhythmias to severe heart failure. Understanding and mitigating these risks is crucial for improving patient outcomes and quality of life.
Researchers are actively investigating new methods to predict and prevent cardiotoxic side effects before they manifest in patients. These efforts include using advanced cell models and sophisticated computer simulations to assess the potential impact of drugs on the heart. By identifying risks early, doctors can make informed decisions about treatment plans, potentially adjusting dosages or selecting alternative therapies that are less harmful to the cardiovascular system.
This article delves into the latest research and strategies for protecting the heart during cancer treatment. We'll explore how scientists are using innovative approaches to identify cardiotoxic risks early, offering hope for safer and more effective cancer therapies.
Cardiotoxicity's Toll Across Treatment Types
Anthracycline cardiotoxicity may manifest years after treatment, and there is still little data on its incidence and natural history in the current context, where protocols increasingly use lower anthracycline doses. Cardiotoxicity has long been associated with trastuzumab, a mainstay of human epidermal growth factor receptor 2 (HER2)-positive breast cancer, and its relationship with anthracyclines is also well established. Retrospective work has assessed cardiotoxicity in patients receiving trastuzumab for HER2-positive breast cancer, while other analyses report figures such as a 20.4% rate within one no-cardiotoxicity reference group. Separately, meta-analyses of selected clinical trials have derived the proportion of patients experiencing cardiotoxicity on bortezomib, illustrating that risk spans multiple drug classes and time frames.
LVEF Limits and the Gold Standard
Standard detection of cardiotoxicity primarily involves serial measurement of left ventricular ejection fraction (LVEF), yet a reduced LVEF is a late manifestation in the course of cardiotoxicity. Cardiac magnetic resonance (CMR) is considered the gold standard for detecting cardiotoxicity because of its accuracy, reproducibility, and ability to detect subtle changes in cardiac function that may be predictive of cardiotoxicity. Each imaging modality carries advantages and limitations, and adoption of standardized assessment protocols remains limited in some settings, such as the cardiotoxicity risk assessment of nanomaterials. Newer electrophysiological models, including human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) used to assay action potentials and sodium currents, are being explored as more sensitive predictors of drug-induced cardiotoxicity, as demonstrated in studies of vandetanib.
From Case Reports to Mechanistic Understanding
Anthracyclines remain important agents in the treatment of solid and hematological malignancy, and early experience with these drugs reported cardiac failure as an adverse event. Later, clinical recognition of cell injury occurring at the time of administration deepened understanding of how these agents damage the heart. This historical arc from early case reporting to mechanistic recognition has shaped how cardiotoxicity is studied across other drug classes, including platinum-based chemotherapy, whose mechanisms, clinical manifestations, detection, and management are now the subject of dedicated reviews. These foundational observations ultimately drove the development and validation of cardiotoxicity detection tools, including algorithms built on specific biomarkers and imaging results.
Predicting Cardiotoxicity with hiPSC-Derived Cardiomyocytes
One promising approach involves the use of human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs). These cells, created from human stem cells, mimic the behavior of actual heart cells and can be used to study the effects of drugs in a controlled laboratory setting. Researchers can expose these cells to various chemotherapeutic agents and monitor their functional and structural responses to assess potential cardiotoxicity.
- Functional Toxicity: Lapatinib altered the excitation-contraction coupling in cardiomyocytes, while sunitinib caused arrhythmic beating.
- Structural Toxicity: Sunitinib induced a dose-dependent release of cTnI, a marker of heart damage, while lapatinib did not significantly affect cTnI levels.
- Cell Viability: Sunitinib reduced cell viability, correlating with the increased release of cTnI.
New Mechanisms, Persistent Late Risk
Recent research has centered on late-onset chronic cardiotoxicity of anthracyclines and on novel molecular mechanisms of doxorubicin cardiotoxicity emerging from cutting-edge mechanistic studies published in influential journals. Reviews of cancer therapy-induced cardiotoxicity emphasize the need to bridge the gap between mechanistic insight and clinical application with more effective strategies. Late cardiotoxicity generally develops several years after treatment, and the risk following breast cancer treatment is increased by cardiovascular risk factors and previous cardiac disease. Future work is expected to focus on understanding these mechanisms and developing improved approaches to prediction and mitigation.
What We Still Don't Know
Despite decades of research, the exact molecular involvement of drug-induced cardiotoxicity is not much clear, and the animal models used to study it have not fully resolved the underlying mechanisms. Advanced imaging modalities offer improved diagnostic capabilities, but they carry their own limitations that constrain routine monitoring. Some statistics report incidences of asymptomatic myocardial dysfunction ranging from 18% to 57% in child cancer survivors, with 5% suffering heart failure problems, underscoring how consequential this problem remains. Researchers also point to persistent research-practice gaps that slow the development of mechanism-based diagnoses and treatments for effective clinical management.
Head-to-Head Cardiotoxicity Evidence
Comparative analyses help quantify differences in cardiotoxicity across treatment regimens. Meta-analytic comparisons have examined the cardiotoxicity odds ratio of pembrolizumab versus nivolumab, and studies of breast cancer chemotherapy have tracked electrocardiogram abnormalities at multiple time points (T0 to T4) in patients who develop cardiotoxicity. In metastatic breast cancer, phase III evidence showed reduced cardiotoxicity and comparable efficacy with pegylated liposomal doxorubicin (CAELYX/Doxil) versus conventional doxorubicin. In metastatic colorectal cancer, a randomized phase III study of 605 patients compared oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment, further illustrating how formulation and administration route affect the cardiotoxic profile.
Future Directions: Towards Safer Cancer Therapies
The development and application of advanced techniques like hiPSC-CMs and PBPK modeling represent significant strides in predicting and preventing drug-induced cardiotoxicity. As research progresses, these tools will likely become integral to the drug development process, helping to ensure that new cancer therapies are both effective and safe for the heart. By prioritizing cardiac safety, we can improve the overall well-being and long-term health of cancer patients.
Who Is at Greatest Risk
Expert opinion identifies specific factors associated with more severe cardiotoxic effects: higher lifetime cumulative doses of anthracyclines, younger age at diagnosis, longer follow-up, female sex, higher dose rates, and cranial irradiation. Analyses of childhood acute lymphoblastic leukemia therapies have examined clinical features and long-term survival outcomes, including a subset of 22 patients followed beyond 18 years of age. Chemotherapy-induced cardiotoxicity is a significant concern in oncology, affecting cancer patients' long-term cardiovascular health, with agents including anthracyclines, HER2-directed therapies, and mitoxantrone among the most studied for their cardiac effects.
Smarter Screening and a Growing Pipeline
The evolving landscape of cancer therapy demands equally advanced strategies to manage cardiotoxicity, and future research is likely to focus on several key areas to achieve that goal. Commercially, the cardiotoxicity screening market is attracting attention for its investment opportunities and commercial adoption patterns. Industry reports such as DelveInsight's "Cardiotoxicity Pipeline Insight, 2024" outline the present clinical development scenario and growth prospects across the cardiotoxicity market, signaling growing confidence that better tools are on the way.
Overlapping Symptoms, Disconnected Care
A core systemic challenge is diagnostic: the symptoms of cardiotoxicity can overlap those caused by cancer treatments themselves, and chemotherapy often produces overlapping toxicities that make it difficult to distinguish general treatment side effects from true cardiotoxicity. This ambiguity complicates decision-making in everyday oncology practice. One proposed remedy is the implementation of cardio-oncology interdisciplinary teams, which is expected to reduce the impact of cancer treatment-associated cardiotoxicity syndromes by bringing cardiology and oncology expertise together at the point of care.
How It Plays Out Beyond Clinical Trials
Real-world studies reveal how cardiotoxicity monitoring unfolds outside the controlled setting of clinical trials. A retrospective study in Eastern Denmark (2019-2022) assessed 108 metastatic melanoma patients treated with encorafenib and binimetinib, while a prospective real-world study followed patients with HR+/HER2-negative metastatic breast cancer treated with palbociclib, ribociclib, or abemaciclib plus endocrine therapy between 2019 and 2024. Case reports add a human dimension: a 67-year-old man with multiple myeloma started a triple regimen of bortezomib, lenalidomide, and dexamethasone and tolerated his first dose without any adverse reaction before experiencing an acute atypical cardiovascular reaction. Across these settings, real-world cardio-oncology practice continues to expose the disconnect between guideline recommendations and everyday clinical realities, pointing to a need for simplified, pragmatic risk assessment tools and standardized surveillance pathways.